These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37876734)

  • 21. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study.
    Dunne S; Shannon B; Dunne C; Cullen W
    BMC Pharmacol Toxicol; 2013 Jan; 14():1. PubMed ID: 23289757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Portuguese generic medicines market: a policy analysis.
    Simoens S
    Pharm Pract (Granada); 2009 Apr; 7(2):74-80. PubMed ID: 25152781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the single exit price policy on a basket of generic medicines in South Africa, using a time series analysis from 1999 to 2014.
    Moodley R; Suleman F
    PLoS One; 2019; 14(7):e0219690. PubMed ID: 31365534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
    Puig-Junoy J
    Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012.
    Lee JSF; Sagaon Teyssier L; Dongmo Nguimfack B; Collins IJ; Lallemant M; Perriens J; Moatti JP
    BMC Pediatr; 2016 Mar; 16():41. PubMed ID: 26979974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries.
    Leopold C; Mantel-Teeuwisse AK; Vogler S; de Joncheere K; Laing RO; Leufkens HG
    Health Policy; 2013 Oct; 112(3):209-16. PubMed ID: 24060335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retail pharmacy prescription medicines' availability, prices and affordability in Eswatini.
    Shambira G; Suleman F
    Afr J Prim Health Care Fam Med; 2021 Sep; 13(1):e1-e11. PubMed ID: 34636605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 34. Generic medicines: solutions for a sustainable drug market?
    Dylst P; Vulto A; Godman B; Simoens S
    Appl Health Econ Health Policy; 2013 Oct; 11(5):437-43. PubMed ID: 23846572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis.
    Moodley R; Suleman F
    BMC Health Serv Res; 2019 Aug; 19(1):576. PubMed ID: 31419977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Product patents and access to innovative medicines.
    Dai R; Watal J
    Soc Sci Med; 2021 Dec; 291():114479. PubMed ID: 34700119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Policies encouraging price competition in the generic drug market: Lessons from the European experience].
    Puig-Junoy J
    Gac Sanit; 2010; 24(3):193-9. PubMed ID: 20189690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.